Search results
3 dni temu · The INTERLACE trial was a multicentre, randomised phase 3 trial done at 32 medical centres in Brazil, India, Italy, Mexico, and the UK. Adults (aged ≥18 years) with locally advanced cervical cancer (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, IIA, IIB, IIIB, or IVA disease) were randomly assigned (1:1), by minimisation, using a central electronic system, to standard ...
8 sie 2023 · Adding pembrolizumab to chemotherapy (paclitaxel plus cisplatin or carboplatin) with or without bevacizumab led to a 37%, 40%, and 42% reduction in the risk of death for all-comer, CPS ≥1, and CPS ≥10 populations, respectively, establishing a new standard of care in the management of PD-L1-positive cervical cancer, with an improved quality ...
3 dni temu · Results from the INTERLACE trial show that giving cervical cancer patients a short course of chemotherapy before starting the standard treatment cuts the risk of death 40%. The new approach also cuts the risk of cervical cancer returning or relapsing (growing again after responding to treatment) by 35%. Around 3,300 women are diagnosed with ...
1 cze 2022 · Chemotherapy is an integral part of the standard cervical cancer treatment regimen and is typically administered as an adjuvant therapy following surgery when poor prognostic tumour features increase the risk of recurrent disease, in combination with radiotherapy as previously mentioned, and as a standalone treatment for locally advanced ...
1 gru 2023 · Novel therapeutic approaches for cervical cancer include combinations of immunotherapy and targeted agents. •. Cervical cancer is associated with financial toxicity, which can impair physical and cancer outcomes. Abstract. Cervical cancer is the most commonly diagnosed gynecologic cancer worldwide.
30 lip 2024 · According to current guidelines, definitive radiotherapy with concomitant chemotherapy represents the gold standard for locally advanced cervical cancer treatment. However, a significant number of patients relapse and die from metastatic disease.
4 lut 2018 · Bevacizumab combined with palliative chemotherapy (cisplatin/paclitaxel or topotecan/paclitaxel) in the first-line treatment for recurrent/metastatic cervical cancer significantly improves overall survival when compared to chemotherapy alone. The role of immunotherapy in cervical cancer remains to be established.
